295 related articles for article (PubMed ID: 33514658)
21. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.
Parker JE; Fishlock KL; Mijovic A; Czepulkowski B; Pagliuca A; Mufti GJ
Br J Haematol; 1998 Dec; 103(4):1075-82. PubMed ID: 9886323
[TBL] [Abstract][Full Text] [Related]
22. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Jilg S; Reidel V; Müller-Thomas C; König J; Schauwecker J; Höckendorf U; Huberle C; Gorka O; Schmidt B; Burgkart R; Ruland J; Kolb HJ; Peschel C; Oostendorp RA; Götze KS; Jost PJ
Leukemia; 2016 Jan; 30(1):112-23. PubMed ID: 26153654
[TBL] [Abstract][Full Text] [Related]
23. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
Tambe M; Karjalainen E; Vähä-Koskela M; Bulanova D; Gjertsen BT; Kontro M; Porkka K; Heckman CA; Wennerberg K
Leukemia; 2020 Dec; 34(12):3186-3196. PubMed ID: 32651543
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
25. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
26. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.
Boehrer S; Adès L; Tajeddine N; Hofmann WK; Kriener S; Bug G; Ottmann OG; Ruthardt M; Galluzzi L; Fouassier C; Tailler M; Olaussen KA; Gardin C; Eclache V; de Botton S; Thepot S; Fenaux P; Kroemer G
Oncogene; 2009 Jun; 28(22):2205-18. PubMed ID: 19398952
[TBL] [Abstract][Full Text] [Related]
27. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Barbacci EG; Pustilnik LR; Rossi AM; Emerson E; Miller PE; Boscoe BP; Cox ED; Iwata KK; Jani JP; Provoncha K; Kath JC; Liu Z; Moyer JD
Cancer Res; 2003 Aug; 63(15):4450-9. PubMed ID: 12907618
[TBL] [Abstract][Full Text] [Related]
28. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
29. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
Han L; Zhang Q; Dail M; Shi C; Cavazos A; Ruvolo VR; Zhao Y; Kim E; Rahmani M; Mak DH; Jin SS; Chen J; Phillips DC; Koller PB; Jacamo R; Burks JK; DiNardo C; Daver N; Jabbour E; Wang J; Kantarjian HM; Andreeff M; Grant S; Leverson JD; Sampath D; Konopleva M
Haematologica; 2020 Mar; 105(3):697-707. PubMed ID: 31123034
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
[TBL] [Abstract][Full Text] [Related]
31. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
32. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
[TBL] [Abstract][Full Text] [Related]
33. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
[TBL] [Abstract][Full Text] [Related]
34. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
35. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
36. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
37. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
38. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
39. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Grosjean-Raillard J; Adès L; Boehrer S; Tailler M; Fabre C; Braun T; De Botton S; Israel A; Fenaux P; Kroemer G
Apoptosis; 2008 Sep; 13(9):1148-61. PubMed ID: 18670883
[TBL] [Abstract][Full Text] [Related]
40. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
